The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Key updates in lymphoma from ASH 2020
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares his highlights from ASH 2020, picking out a presentation of early data from the TRANSCEND-NHL-001 study (NCT02631044) investigating the safety and efficacy of lisocabtagene maraleucel for relapsed/refractory mantle cell lymphoma (MCL) and a Phase II study (NCT03618550) investigating a novel combination of pembrolizumab plus gemcitabine, vinorelbine and liposomal doxorubicin for relapsed/refractory Hodgkin lymphoma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
